Advertisement
ISRG vs NTRA
Which Stock Would AI Choose? Intuitive Surgical (ISRG) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- ISRG reported Q2 2026 revenue of $2.89 billion, beating estimates, but shares declined amid concerns over slowing U.S. procedure growth and a product recall.
- NTRA stock has shown strong longer-term momentum with over 100% one-year returns in recent data, driven by oncology testing products like Signatera.
- ISRG operates in robotic-assisted surgery with a mature installed base, while NTRA focuses on cell-free DNA diagnostics in prenatal and oncology markets.
- Recent market activity shows ISRG trading near the lower end of its 52-week range around $353, contrasting with NTRA’s higher volatility and premium valuation near $252–$268.
- Both companies face healthcare sector risks including regulatory changes and reimbursement pressures, with NTRA set to report Q2 results shortly after the latest data cutoff.
- Relative performance highlights trade-offs between ISRG’s established procedure volumes and NTRA’s growth-oriented diagnostics expansion.
Introduction
This comparison examines ISRG and NTRA, two healthcare stocks with distinct business models in medical technology and diagnostics. Traders and investors seeking exposure to innovation-driven segments may find the analysis relevant for assessing relative momentum, risk profiles, and positioning within the broader market. The review draws on verifiable recent developments to highlight contrasts in performance and sector dynamics without projecting future outcomes.
ISRG Overview and Recent Performance
ISRG, Intuitive Surgical, develops and markets robotic surgical systems, primarily the da Vinci platform used across multiple surgical specialties. In recent weeks, the company delivered Q2 results with revenue reaching $2.89 billion, exceeding analyst expectations, and adjusted earnings per share of $2.80. Despite the beat, shares faced downward pressure linked to reports of moderating U.S. procedure volumes and a Class II recall affecting certain components. Stock activity reflected broader sentiment shifts, with the price settling near $353 amid a 52-week range of approximately $329 to $604. Market positioning has emphasized long-term procedure growth potential offset by short-term volume concerns.
NTRA Overview and Recent Performance
NTRA, Natera, specializes in cell-free DNA testing for applications including non-invasive prenatal testing and oncology monitoring through products such as Signatera. Recent market activity shows the stock maintaining elevated levels near $252–$268, supported by optimism around oncology offerings and a one-year return exceeding 100% in available data. The company is scheduled to release Q2 2026 results in early August, with prior periods reflecting revenue expansion and focus on precision medicine. Performance has featured notable volatility consistent with growth-oriented diagnostics peers, alongside a 52-week range spanning roughly $132 to $288.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and risk parameters tailored to prevailing market conditions. Only those demonstrating strong statistical profiles in backtested and live performance metrics earn placement in the trending section. Available bots exhibit diverse win rates, profit factors, and drawdown statistics, enabling users to explore options suited to different styles such as trend-following or mean-reversion approaches. Review the Trending AI Robots page for current selections and detailed metrics.
Head-to-Head Comparison
ISRG and NTRA differ markedly in business models: the former centers on capital equipment and recurring procedure revenue in robotic surgery, while the latter emphasizes recurring testing volume in genetic diagnostics. Growth drivers for ISRG include system utilization and new indications, tempered recently by volume softness; NTRA benefits from expanding adoption of oncology assays amid broader precision medicine trends. Recent momentum favors NTRA on longer-term returns, whereas ISRG has encountered post-earnings pressure. Risk factors include regulatory scrutiny for both, with ISRG additionally exposed to hospital capital spending cycles and NTRA to reimbursement variability. Sector exposure places them in healthcare innovation, though market sentiment has reflected contrasting reactions to earnings visibility and product-specific catalysts.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings delivery, and relative positioning, Tickeron’s AI models currently indicate a probabilistic preference toward NTRA due to stronger longer-term momentum and oncology catalysts, while acknowledging ISRG’s established base and recent earnings resilience. This assessment draws from available performance patterns and does not constitute investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ISRG is a Buy and NTRA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ISRG’s FA Score shows that 0 FA rating(s) are green whileNTRA’s FA Score has 1 green FA rating(s).
- ISRG’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ISRG’s TA Score shows that 7 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
- ISRG’s TA Score: 7 bullish, 2 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
ISRG (@Pharmaceuticals: Other) experienced а +6.95% price change this week, while NTRA (@Medical Specialties) price change was +15.07% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +6.41%. For the same industry, the average monthly price growth was +10.59%, and the average quarterly price growth was +7.31%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.62%. For the same industry, the average monthly price growth was +7.93%, and the average quarterly price growth was +24.12%.
Reported Earning Dates
ISRG is expected to report earnings on Oct 20, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+6.41% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+0.62% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ISRG | NTRA | ISRG / NTRA | |
| Capitalization | 142B | 44.8B | 317% |
| EBITDA | 4.25B | -227.7M | -1,864% |
| Gain YTD | -29.149 | 37.920 | -77% |
| P/E Ratio | 46.02 | N/A | - |
| Revenue | 11B | 2.5B | 440% |
| Total Cash | 5.22B | 1.09B | 479% |
| Total Debt | 87M | 240M | 36% |
ISRG | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 21 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 82 | 22 | |
SMR RATING 1..100 | 51 | 96 | |
PRICE GROWTH RATING 1..100 | 62 | 36 | |
P/E GROWTH RATING 1..100 | 83 | 100 | |
SEASONALITY SCORE 1..100 | 46 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (49) in the Biotechnology industry is in the same range as ISRG (74) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ISRG’s over the last 12 months.
NTRA's Profit vs Risk Rating (22) in the Biotechnology industry is somewhat better than the same rating for ISRG (82) in the Medical Specialties industry. This means that NTRA’s stock grew somewhat faster than ISRG’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for NTRA (96) in the Biotechnology industry. This means that ISRG’s stock grew somewhat faster than NTRA’s over the last 12 months.
NTRA's Price Growth Rating (36) in the Biotechnology industry is in the same range as ISRG (62) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's P/E Growth Rating (83) in the Medical Specialties industry is in the same range as NTRA (100) in the Biotechnology industry. This means that ISRG’s stock grew similarly to NTRA’s over the last 12 months.
| ISRG | NTRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 58% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 81% |
| Advances ODDS (%) | 2 days ago 66% | 10 days ago 80% |
| Declines ODDS (%) | 15 days ago 61% | 3 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 65% | 2 days ago 71% |
| Aroon ODDS (%) | 7 days ago 73% | 2 days ago 80% |
Advertisement
ISRG and
Correlation & Price change
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | +0.01% | ||
| BSX - ISRG | 73% Closely correlated | +0.45% | ||
| SYK - ISRG | 64% Loosely correlated | -0.27% | ||
| NTRA - ISRG | 54% Loosely correlated | +1.04% | ||
| GKOS - ISRG | 51% Loosely correlated | +2.54% | ||
| PODD - ISRG | 49% Loosely correlated | +0.25% | ||
More | ||||
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +1.04% | ||
| ISRG - NTRA | 53% Loosely correlated | +0.01% | ||
| GH - NTRA | 50% Loosely correlated | +0.01% | ||
| ADPT - NTRA | 50% Loosely correlated | -0.55% | ||
| MTD - NTRA | 47% Loosely correlated | +0.09% | ||
| GKOS - NTRA | 47% Loosely correlated | +2.54% | ||
More | ||||